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ajog.org Poster Session IICONCLUSION: Teleultrasound is inferior to on-site ultrasound in the
detection of fetal anomalies. However, clinically, a negative tele-
ultrasound is more likely to identify a non-anomalous fetus and a
positive teleultrasound is more likely to correctly identify an
anomalous fetus. Therefore, teleultrasound has an important role in
prenatal diagnosis for those patients unable or unwilling to travel for
an on-site ultrasound.437 Underlying etiologies in prenatally-diagnosed
non-immune hydrops fetalis
Teresa N. Sparks1, Kao Thao1, Billie Lianoglou1, Ilina Datkhaeva2,
Victoria Fratto3, Louise Laurent3, Anne H. Mardy1,
Aisling M. Murphy2, Lisa Wilson1, Mary E. Norton1
1University of California, San Francisco, San Francisco, CA, 2University of
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OBJECTIVE: Since the introduction of Rh(D) immune globulin, non-
immune hydrops fetalis (NIHF) now constitutes the majority of
hydrops cases. A myriad of genetic, structural, and other abnor-
malities have been associated with NIHF, yet after prenatal standard
work up, the etiology often remains unclear. Our objective was to
examine the clinical characteristics and etiologies in a diverse cohort
of prenatally-diagnosed NIHF cases.
STUDY DESIGN: This was a retrospective cohort study of NIHF cases
evaluated between January 2015 and January 2017 at three Univer-
sity of California Fetal-Maternal Consortium (UCfC) sites: UC Los
Angeles, UC San Diego, and UC San Francisco. Exclusion criteria
were multiple gestations and Rh isoimmunization. Each NIHF case
was managed according to standard practice at each site and society
recommendations. Clinical data were extracted for each case,
including demographic information, obstetric and family history
(FH), results of work up performed, and delivery and infant
outcomes.
RESULTS: 29 cases of NIHF were identiﬁed. Cohort characteristics
included a median maternal age of 31 years (17-42), 44.8% (13/29)
nulliparous, 6.9% (2/29) with a prior stillbirth, and another 6.9% (2/
29) with a prior pregnancy with NIHF. There was one case each
(3.5%) with a family history of stillbirth, recurrent pregnancy loss,
early childhood death (unknown cause), hemoglobinopathy (He-
moglobin H disease), chromosomal abnormality (Down syndrome),
and other genetic disorder (Friedrich’s ataxia). Consanguinity was
identiﬁed in 6.9% (2/29). Table 1 shows associated structural
anomalies, genetic work up, and outcomes. In addition, infectious
work up yielded results potentially of clinical signiﬁcance in two
cases (one + Parvovirus IgM, one + HSV IgM). A clear etiology of
the NIHF was felt evident in 17.2% (5/29).
CONCLUSION: Structural congenital anomalies were present in 65% of
NIHF cases, although a genetic diagnosis was not clearly established
in the majority of cases. The work up performed for NIHF was very
variable, and points to the need for further research to clarify the
optimal pathway for evaluation.Supplem438 Accuracy of selective fetal echocardiography
for the diagnosis of congenital heart disease in
patients with pregestational diabetes stratified by
hemoglobin A1c
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OBJECTIVE: To evaluate the accuracy of antenatal diagnosis of
congenital heart disease (CHD) in patients with pregestational dia-
betes using screening methods including a combination of elevated
hemoglobin A1c, level II ultrasound, and fetal echocardiography.
STUDY DESIGN: Retrospective cohort study of all pregnancies
complicated by pregestational diabetes from 1/2012-12/2016 with an
early hemoglobin A1c <20 weeks gestation who underwent both a
level II ultrasound and fetal echocardiography. Sensitivity, speciﬁcity,
PPV, and NPV were calculated for each screening regimen. Absence
of congenital heart disease was conﬁrmed by either a normal post-
natal exam or normal neonatal echocardiogram.
RESULTS: 378 patients met inclusion criteria during the study period
with an overall prevalence of CHD of 3.97% (n¼15). When
compared to level II ultrasound, fetal echocardiography had a higher
sensitivity (73.3% vs. 40.0%) and slightly lower speciﬁcity (98.9% vs.
100%). All clinically signiﬁcant CHD was detected by level II ul-
trasound (n¼6) with the remainder being septal defects. Early A1c
was higher in pregnancies affected by CHD (9.0%; IQR: 6.4-9.9 vs.
7.1%; IQR: 6.1-8.6, p¼.034). A ROC curve showed an A1c of >7.7%
as the best cut off for detection of CHD (AUC: 0.66, p¼.038). An
elevated early A1c >7.7% combined in parallel with level II ultra-
sound resulted in a sensitivity and speciﬁcity of 84.0% and 65.4%,
respectively. The negative predictive value for all screening regimens
was high (level II: 97.6%; level II + A1c 99.0%; fetal echo 98.9%).
The use of selective fetal echocardiography for an A1c >7.7% or
abnormal level II ultrasound would result in a 57.2% reduction in
the use of fetal echocardiography with a similar detection rate as
universal fetal echocardiography.
CONCLUSION: The use of selective fetal echocardiography in preg-
nancies complicated by pregestational diabetes with an early A1c
>7.7% would result in a substantial cost savings with a similar
detection rate when compared to universal echocardiography.
Overall, fetal echocardiography appears to have limited value as a
level II ultrasound detected all cases of clinically signiﬁcant CHD.ent to JANUARY 2018 American Journal of Obstetrics & Gynecology S265
